For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis today announced that an extraordinary general meeting of shareholders held on 17 September 2018 elected biotech investment specialist Edward Rayner as a non-executive director of the Company. Mr Rayner is an investment director at Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, and led the Arix investment in the recent Pharmaxis share placement after which it holds 11 percent of the Company. Before joining Arix Bioscience at its inception, Mr Rayner spent 18 years as an equity analyst and portfolio manager in Europe and Australia. From 2004 to 2014, he was based in Sydney Australia, initially as head of research at Alliance Bernstein and then a senior portfolio manager at AMP Capital where he managed the growth equity portfolios and launched a small companies fund. As part of his responsibilities he focused on the healthcare sector.Read full media release - pdf
Chairman's introductory comments at the extraordinary general meeting held on 17 September 2018 at 2.30pmRead full ASX announcement – pdf
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced the company has received approval from the United States Food and Drug Administration (FDA) for its manufacturing facility to produce the asthma diagnostic product Aridol for the US market.Read full media release - pdf